Semaglutide is a GLP-1 receptor agonist originally developed to help people with type 2 diabetes manage blood sugar levels
Federici M, Giaccari A, Hribal ML, Giovannone B, Lauro D, Morviducci L, Pastore L, Tamburrano G, Lauro R, Sesti G
This medications triple-action approach surpasses what traditional weight-loss medications can do by targeting multiple pathways simultaneously
GLP-1 drugs slow digestion and suppress appetite, which can cause low energy from reduced nutrient intake or blood sugar fluctuations
By promoting the undocking of secretory granules, GLP1(936) reduces the number of granules available for exocytosis, further limiting glucagon release
This is one of the clearest signs that the medication is no longer safe to use